Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Mol Biol Rep ; 50(7): 6039-6047, 2023 Jul.
Article in English | MEDLINE | ID: covidwho-20245262

ABSTRACT

BACKGROUND: Diabetic patients infected with coronavirus disease 2019 (COVID-19) often have a higher probability of organ failure and mortality. The potential cellular mechanisms through which blood glucose exacerbates tissue damage due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still unclear. METHODS AND RESULTS: We cultured endothelial cells within differing glucose mediums with an increasing concentration gradient of SARS-CoV-2 Spike protein (S protein). S protein can cause the reduction of ACE2 and TMPRSS2, and activation of NOX2 and NOX4. A high glucose medium was shown to aggravate the decrease of ACE2 and activation of NOX2 and NOX4 in cultured cells, but had no effect on TMPRSS2. S protein mediated activation of the ACE2-NOX axis induced oxidative stress and apoptosis within endothelial cells, leading to cellular dysfunction via the reduction of NO and tight junction proteins which may collectively be exacerbated by elevated glucose. In addition, the glucose variability model demonstrated activation of the ACE2-NOX axis in a similar manner observed in the high glucose model in vitro. CONCLUSIONS: Our present study provides evidence for a mechanism through which hyperglycemia aggravates endothelial cell injury resulting from S protein mediated activation of the ACE2-NOX axis. Our research thus highlights the importance of strict monitoring and control of blood glucose levels within the context of COVID-19 treatment to potentially improve clinical outcomes.


Subject(s)
COVID-19 , Humans , SARS-CoV-2/metabolism , Spike Glycoprotein, Coronavirus/metabolism , Reactive Oxygen Species , Endothelial Cells/metabolism , Angiotensin-Converting Enzyme 2 , Blood Glucose , COVID-19 Drug Treatment , Peptidyl-Dipeptidase A/metabolism
2.
Chinese Journal of Disease Control and Prevention ; 25(4):395-399 and 453, 2021.
Article in Chinese | Scopus | ID: covidwho-1566852

ABSTRACT

Objective To explore the effect of COVID-19 pandemic on chronic disease treatment and health condition among Chinese adults. Methods  Random digital dialing method was used to extract respondents aged 18 years old and over from all prefectural level areas in China. A cloud-based telephone interviewing system was administered to do the questionnaire survey. A total number of 5 972 questionnaires were collected nationally from November to December 2020. Results  The COVID-19 pandemic had some or high degree impact on hypertension treatment of 2.2% self-reported patients. In addition, 4.6% and 8.8% of patients with dyslipidemia and diabetes or high glucose were affected by COVID-19. Compared with prepandemic, a total number of 4.2% population reported a little bit or significantly worse health condition. Results showed that the treatment of hypertension was affected more by COVID-19 pandemic among patients with worse health condition. The treatment of dyslipidemia was affected more by COVID-19 pandemic among old age and low family income patients with worse health condition. Middle and old age, urban people had higher chance to getting worse heath during COVID-19 pandemic. Conclusions  The COVID-19 pandemic has little impact on treatment of hypertension, dyslipidemia, diabetes or high glucose patients and overall health status among Chinese population at present. But special attention should paid to high risk population with chronic disease who disproportionately affected by pandemic. © 2021, Publication Centre of Anhui Medical University. All rights reserved.

3.
J Am Coll Nutr ; 40(4): 327-332, 2021.
Article in English | MEDLINE | ID: covidwho-1087590

ABSTRACT

Objective: Vitamin D deficiency is common in the general population and diabetic patients, and supplementation with vitamin D is widely used to help lower oxidative stress and inflammation. The cytokine storm in SARS-CoV2 infection has been linked with both diabetes and Vitamin D deficiency. This study examined the hypothesis that supplementation with vitamin D, in combination with l-cysteine (LC), is better at reducing oxidative stress and thereby, more effective, at inhibiting the secretion of the pro-inflammatory cytokines, Interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) in U937 monocytes exposed to high glucose concentrations. Methods: U937 monocytes were pretreated with 1,25 (OH)2 vitamin D (VD, 10 nM) or LC (250 µM) or VD + LC for 24 h and then exposed to control or high glucose (HG, 25 mM) for another 24 h. Results: There were significantly greater reactive oxygen species (ROS) levels in monocytes treated with HG than those in controls. Combined supplementation with VD and LC showed a more significant reduction in ROS (46%) in comparison with treatment with LC (19%) or VD (26%) alone in monocytes exposed to HG. Similarly, VD supplementation, together with LC, caused a more significant inhibition in the secretion of IL-8 (36% versus 16%) and MCP-1 (46% versus 26%) in comparison with that of VD (10 nM) alone in high-glucose treated monocytes. Conclusions: These results suggest that combined supplementation with vitamin D and LC has the potential to be more effective than either VD or LC alone in lowering the risk of oxidative stress and inflammation associated with type 2 diabetes or COVID-19 infection. Further, this combined vitamin D with LC/N-acetylcysteine may be a potent alternative therapy for SARS-CoV2 infected subjects. This approach can prevent cellular damage due to cytokine storm in comorbid systemic inflammatory conditions, such as diabetes, obesity, and hypertension.


Subject(s)
COVID-19 Drug Treatment , Cysteine/administration & dosage , Oxidative Stress/drug effects , SARS-CoV-2/immunology , Vitamin D/administration & dosage , COVID-19/immunology , Chemokine CCL2/metabolism , Diabetes Mellitus, Type 2/drug therapy , Dietary Supplements , Drug Therapy, Combination , Glucose/administration & dosage , Humans , Interleukin-8/metabolism , Monocytes/immunology , Monocytes/virology , U937 Cells , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/immunology , Vitamin D Deficiency/virology
SELECTION OF CITATIONS
SEARCH DETAIL